

December 14, 2017

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

Sub: Launch of XIGDUO XR[®]

We refer to our communication dated October 17, 2017, with regard to receipt of Import and Market Permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin + Metformin Hydrochloride film coated tablets (XIGDUO XR[®])

With regard to the same, we further wish to update that, subject to the receipt of Import License from the Drugs Controller General of India, the FDC of Dapagliflozin + Metformin Hydrochloride film coated tablets (XIGDUO XR[®]) is expected to be launched in India in Q4 of FY 2017-18.

XIGDUO XR[®] is a product of AstraZeneca Group and has been approved in 61 countries to date including US, EU and Japan.

XIGDUO XR[®] is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate.

Kindly take the same on record.

Thanking you,

For **AstraZeneca Pharma India Limited**



Pratap Rudra

Company Secretary & Legal Counsel

CORPORATE & REGD. OFFICE
AstraZeneca Pharma India Ltd.
P. B. No. 4525, Block N1, 12th Floor,
Manyata Embassy Business Park,
Rachenahalli, Outer Ring Road,
Bangalore - 560 045, INDIA

TEL : +91 80 6774 8000
FAX : +91 80 6774 8857
CIN : L24231KA1979PLC003563
WEB : www.astrazeneca.com/india

FACTORY
12th Mile on Bellary Road
Venkatala, Kattigenahalli Village
Yelahanka
Bangalore - 560 063
INDIA

TEL : +91 80 6774 9000
FAX : +91 80 2846 2208
+91 80 6774 9628